Dec 5 (Reuters) - Edgewise Therapeutics Inc EWTX.O:
EDGEWISE PROVIDES STATEMENT REGARDING COMPANY’S RELATIONSHIP WITH DR. HAN PHAN AT RARE DISEASE RESEARCH
EDGEWISE THERAPEUTICS- BELIEVES DATA RELATED TO CO'S CLINICAL TRIALS AT PHAN'S SITE ARE ACQUIRED & STORED IN ACCORDANCE WITH FDA REQUIREMENTS
EDGEWISE THERAPEUTICS: WARNING LETTER BY FDA TO DR. HAN PHAN IS UNRELATED TO ANY EDGEWISE CLINICAL TRIAL OR DATA
Source text: ID:nBw64fywa
Further company coverage: EWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.